pharma · Pain · Hyponatremia · CPIX
Cumberland Pharmaceuticals
CUMBERLAND PHARMACEUTICALS INC
Cumberland Pharmaceuticals clinical programs — 53 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1600 W End Ave, #1300, Nashville, Tennessee 37203, US
- Founded
- 1999
- Employees
- 128
- Programs
- 53
- Drugs
- 26
- Patents
- 34
Cumberland Pharmaceuticals projects
53 ClinicalTrials.gov programs sponsored by Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals has 53 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Telavancin Injection
CUMBERLAND PHARMACEUTICALS INC
Cystic Fibrosis
1 trial -
Telavancin Injection
CUMBERLAND PHARMACEUTICALS INC
Subarachnoid Hemorrhage, Aneurysmal
1 trial -
intravenous NAC
CUMBERLAND PHARMACEUTICALS INC
Nephropathy
1 trial -
lactulose (Kristalose®)
CUMBERLAND PHARMACEUTICALS INC
Constipation
1 trial -
placebo
CUMBERLAND PHARMACEUTICALS INC
Autism
1 trial
Frequently asked questions
How many clinical projects does Cumberland Pharmaceuticals have?
53 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.